NASDAQ:STIM - Neuronetics Stock Price, Forecast & News

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Neuronetics Inc (NASDAQ:STIM) announced its earnings results on Tuesday, November, 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.04. The business earned $16 million during the quarter, compared to analyst estimates of $16.13 million. Neuronetics had a negative return on equity of 44.10% and a negative net margin of 45.35%. View Neuronetics' Earnings History.

Neuronetics is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Neuronetics.

2 Wall Street analysts have issued 1-year target prices for Neuronetics' shares. Their forecasts range from $11.00 to $28.00. On average, they anticipate Neuronetics' stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 344.2% from the stock's current price. View Analyst Price Targets for Neuronetics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neuronetics.

Headlines about STIM stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Neuronetics earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Neuronetics.

Neuronetics saw a decline in short interest in December. As of December 31st, there was short interest totalling 246,900 shares, a decline of 11.1% from the December 15th total of 277,700 shares. Based on an average daily volume of 146,400 shares, the short-interest ratio is currently 1.7 days. Approximately 2.9% of the shares of the company are short sold. View Neuronetics' Current Options Chain.

Some companies that are related to Neuronetics include Accuray (ARAY), SeaSpine (SPNE), Iradimed (IRMD), Pulse Biosciences (PLSE), GenMark Diagnostics (GNMK), Apyx Medical (APYX), Westaim (WEDXF), RenovaCare (RCAR), Vapotherm (VAPO), Restoration Robotics (HAIR), Repro-Med Systems (REPR), Repro Med Systems (KRMD), Soliton (SOLY), iCAD (ICAD) and Venus Concept (VERO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include Anavex Life Sciences (AVXL), Nektar Therapeutics (NKTR), Ocular Therapeutix (OCUL), Progenics Pharmaceuticals (PGNX), Athenex (ATNX), AVEO Pharmaceuticals (AVEO), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS), Corbus Pharmaceuticals (CRBP) and Crispr Therapeutics (CRSP).

(STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Neuronetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.40%). Company insiders that own Neuronetics stock include Brian E Farley, Christopher Thatcher, Daniel Guthrie, Gregory Harper, Peter Donato, Stephen Furlong, Stephen M Campe and Wilfred E Jaeger. View Institutional Ownership Trends for Neuronetics.

STIM stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Neuronetics stock in the last two years include Brian E Farley, Daniel Guthrie, Gregory Harper, Stephen Furlong, Stephen M Campe and Wilfred E Jaeger. View Insider Buying and Selling for Neuronetics.

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of STIM stock can currently be purchased for approximately $4.39.

Neuronetics has a market capitalization of $81.79 million and generates $52.78 million in revenue each year. The company earns $-24,100,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Neuronetics employs 191 workers across the globe.View Additional Information About Neuronetics.

The official website for Neuronetics is http://www.neurostar.com/.

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]